Biomea Fusion Reports Phase 1 Trial Results for Oral Weight-Loss Drug BMF-650
Biomea Fusion, Inc. (NASDAQ:BMEA) reported Phase 1 clinical trial results for BMF-650, an investigational oral weight-loss therapy. Across four weeks of testing in multiple dose groups, trial participants experienced consistent weight reduction. In outpatient cohorts receiving daily doses of 200 milligrams or higher, average weight loss reached approximately 0.97 kilograms per week, with total four-week weight reduction ranging between 1.5% and 3.2%. An additional inpatient cohort receiving up to 400 milligrams daily showed an average 6.1% weight reduction, though altered eating habits in confinement influenced results for both active and placebo groups.
The study showed encouraging safety outcomes, with side effects limited to mild or moderate symptoms such as nausea, vomiting, and constipation. No severe adverse events or trial dropouts were reported. Biomea Fusion, Inc. (NASDAQ:BMEA) engineered BMF-650 to minimize gastrointestinal side effects and allow rapid dose progression, successfully advancing patients to the maximum 400-milligram dose after a single one-week step. This contrasts with current GLP-1 drugs that often require multi-month dose escalation periods.
Biomea Fusion, Inc. plans to conduct longer-term toxicology studies while seeking a strategic partner to fund late-stage development and commercialization for BMF-650. The company stated that its internal primary development focus remains on icovamenib, a treatment for type 1 and type 2 diabetes currently in Phase 2 trials. Shares of the biopharmaceutical company fell 7.35% to $1.26 following the announcement.
Key points
- Biomea Fusion, Inc. (NASDAQ:BMEA) released Phase 1 trial data for its oral GLP-1 weight-loss drug candidate BMF-650.
- Outpatient participants taking 200 mg or higher daily lost an average of 0.97 kg per week over four weeks.
- All adverse events were mild or moderate, with zero severe side effects or patient discontinuations.
- Biomea intends to seek a strategic partner for BMF-650 while focusing internal work on diabetes drug icovamenib.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were the key Phase 1 results for Biomea Fusion BMF-650?
In a four-week Phase 1 trial, outpatient participants taking 200 mg or more daily lost an average of 0.97 kg per week. Side effects were mild to moderate, and no participants dropped out due to treatment-emergent adverse events.
What are Biomea Fusion plans for BMF-650?
Biomea Fusion plans to complete long-term toxicology studies and look for a strategic partner for late-stage development and commercialization, keeping its main internal focus on its diabetes drug icovamenib.